Abstract
A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 606-611 |
| Number of pages | 6 |
| Journal | Seminars in Oncology |
| Volume | 26 |
| Issue number | 6 |
| State | Published - 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Drug resistance in colon cancer. / Gorlick, R.; Bertino, J. R.
In: Seminars in Oncology, Vol. 26, No. 6, 1999, p. 606-611.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Drug resistance in colon cancer
AU - Gorlick, R.
AU - Bertino, J. R.
PY - 1999
Y1 - 1999
N2 - A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.
AB - A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.
UR - http://www.scopus.com/inward/record.url?scp=0033400231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033400231&partnerID=8YFLogxK
M3 - Article
C2 - 10606253
AN - SCOPUS:0033400231
VL - 26
SP - 606
EP - 611
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 6
ER -